Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections
| Autor: | Maria Caterina Pace, Emanuele Durante-Mangoni, Roberto Andini, Roberto Giurazza, Pasquale Sansone, Maria Civita Mazza |
|---|---|
| Přispěvatelé: | Giurazza, R., Mazza, M. C., Andini, R., Sansone, P., Pace, M. C., Durante-Mangoni, E. |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Brand-new antibiotic brand-new antibiotics medicine.medical_specialty medicine.drug_class Science 030106 microbiology Ceftobiprole Antibiotics Review resistance mechanisms Plazomicin General Biochemistry Genetics and Molecular Biology emerging infectious diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Antibiotic resistance Old revived antibiotic Antimicrobial stewardship Medicine antimicrobial resistance 030212 general & internal medicine Intensive care medicine Ecology Evolution Behavior and Systematics extensively drug resistant business.industry place in therapy Emerging infectious disease Paleontology Antimicrobial Eravacycline old revived antibiotics drug therapy chemistry Space and Planetary Science Tedizolid business |
| Zdroj: | Life Life, Vol 11, Iss 519, p 519 (2021) |
| ISSN: | 2075-1729 |
| DOI: | 10.3390/life11060519 |
| Popis: | Antimicrobial resistance (AMR) remains one of the top public health issues of global concern. Among the most important strategies for AMR control there is the correct and appropriate use of antibiotics, including those available for the treatment of AMR pathogens. In this article, after briefly reviewing the most important and clinically relevant multi-drug-resistant bacteria and their main resistance mechanisms, we describe the emerging antimicrobial options for both MDR Gram-positive cocci and Gram-negative bacilli, including recently marketed agents, molecules just approved or under evaluation and rediscovered older antibiotics that have regained importance due to their antimicrobial spectrum. Specifically, emerging options for Gram-positive cocci we reviewed include ceftaroline, ceftobiprole, tedizolid, dalbavancin, and fosfomycin. Emerging treatment options for Gram-negative bacilli we considered comprise ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, minocycline, fosfomycin, eravacycline, plazomicin, and cefiderocol. An exciting scenario is opening today with the long awaited growing availability of novel molecules for the treatment of AMR bacteria. Knowledge of mechanisms of action and resistance patterns allows physicians to increasingly drive antimicrobial treatment towards a precision medicine approach. Strict adherence to antimicrobial stewardship practices will allow us to preserve the emerging antimicrobials for our future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|